EMA sounds its own safe­ty alarm for Pfiz­er block­buster, but they’re al­so not forc­ing a lim­it on dos­ing — yet

The Eu­ro­pean Med­i­cines Agency has is­sued a for­mal warn­ing for pa­tients and physi­cians to stick with the rec­om­mend­ed dose of Xel­janz for treat­ing rheuma­toid arthri­tis and to watch out for po­ten­tial­ly lethal blood clots.

Pfiz­er has been be­dev­iled by a clear safe­ty sig­nal on their block­buster JAK in­hibitor, flag­ging the risk of blood clots and death for the twice dai­ly 10 mg dose of Xel­janz, which is au­tho­rized at 5 mg twice a day for RA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER